Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AM 1030: A Phase I/II, Double-Blind, Placebo-Controlled, Single and Multiple Ascending (Topical) Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Patients (Male and Female) with Atopic Dermatitis

Trial Profile

AM 1030: A Phase I/II, Double-Blind, Placebo-Controlled, Single and Multiple Ascending (Topical) Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Patients (Male and Female) with Atopic Dermatitis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AM 1030 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors AnaMar AB
  • Most Recent Events

    • 11 Aug 2015 According to an AnaMar media release, headline data from this trial is expected to be released in September 2015.
    • 11 Aug 2015 Status changed from recruiting to completed, according to an AnaMar media release.
    • 12 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top